PSMB9 and Hodgkins lymphoma: EBVSTs targeting type II latency antigens (EBNA1, LMP1, and LMP2) have shown promising results in clinical trials (85, 87, 88, 117, 125), with increased response rates and overall survival observed in patients with NPC and HL compared to those who did not receive adoptive cell transfer.